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Abstract
Objectives: Our study aimed to assess adult women’s knowledge of human papillomavirus (HPV) and cervical cancer, and
characterize their attitudes towards potential screening and prevention strategies.
Methods: Women were participants of an HIV-discordant couples cohort in Nairobi, Kenya. An interviewer-administered
questionnaire was used to obtain information on sociodemographic status, and sexual and medical history at baseline and
on knowledge and attitudes towards Pap smears, self-sampling, and HPV vaccination at study exit.
Results: Only 14% of the 409 women (67% HIV-positive; median age 29 years) had ever had a Pap smear prior to study
enrollment and very few women had ever heard of HPV (18%). Although most women knew that Pap smears detect cervical
cancer (69%), very few knew that routine Pap screening is the main way to prevent ICC (18%). Most women reported a high
level of cultural acceptability for Pap smear screening and a low level of physical discomfort during Pap smear collection. In
addition, over 80% of women reported that they would feel comfortable using a self-sampling device (82%) and would
prefer at-home sample collection (84%). Nearly all women (94%) reported willingness to be vaccinated to prevent cervical
cancer if offered at no or low cost.
Conclusions: These findings highlight the need to educate women on routine use of Pap smears in the prevention of
cervical cancer and demonstrate that vaccination and self-sampling would be acceptable modalities for cervical cancer
prevention and screening.
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Introduction
Cervical cancer is a preventable disease, yet the number of cases
globally is expected to almost double by the year 2025 [1].
Infection with high-risk genotypes of human papillomavirus (HR-
HPV) is the primary cause of invasive cervical cancer; over 70% of
all cervical cancers are attributable to infection with HPV-16 and
18 [2,3]. Cervical cancer is the third most common cancer among
women worldwide with an estimated 529,000 new cases in 2008,
85% of which occur in developing countries [4]. In 2008, WHO
estimated that cervical cancer was the second most common
cancer among Kenyan women [1], yet screening coverage is
currently very low, according to the Kenyan national cervical
cancer prevention strategic plan for 2012–2015 released in
January of 2012 [5].
Traditionally, Pap smear, combined with treatment of cervical
precancer and early stage cancer, has been successful in preventing
up to 80% of invasive cervical cancer cases in developed countries
[6,7,8]. In developing countries, however, high rates of cervical
cancer mortality persist due to lack of effective screening programs
and low uptake of Pap smear testing [9]. Reasons cited for the low
uptake of screening include lack of awareness, inadequate access,
exam discomfort, fear of finding cancer and logistical issues
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e40766
associated with obtaining screening [10,11]. Newer technologies
such as the careHPV DNA test (QIAGEN, Gaithersburg, MD,
USA), cervico-vaginal self-sampling, and HPV vaccination have
the potential to increase screening and reduce cervical cancer in
developing countries [12,13,14].
Uptake of self-sampling has been shown to be successful and
HPV testing from self-collected samples is highly sensitive for
detection of cervical intraepithelial neoplasia grade 2/3 in both
clinic and home settings [15,16,17]. Previous studies have shown
that African women find self-sampling acceptable; for example,
80% of Ugandan women were willing to collect their own samples
at home [18]. However, knowledge of new screening and cervical
cancer prevention technologies remains low among most women,
with studies documenting almost no awareness of HPV infection,
HPV screening for women 30 years and older and adolescent
vaccination for the prevention of future disease
[10,19,20,21,22,23,24]. Awareness is even low among healthcare
workers who are expected to provide preventative health services
[25,26,27].
With the increase in technology and opportunity to prevent
cervical cancer worldwide, it is important to understand attitudes
and barriers of screening among women at high-risk of invasive
cervical cancer in low-resource settings. Therefore, our study
aimed to assess women’s knowledge of HPV and cervical cancer,
and their attitudes towards potential screening strategies, including
routine Pap smears, self-sampling for HPV DNA testing, and HPV
vaccination. These data will be critical for successful implemen-
tation and high uptake of community-level cervical cancer
screening programs.
Methods
Study Population and Design
Women were recruited into a cohort of HIV-1-discordant
couples identified in voluntary counseling and testing centers in
Nairobi, Kenya, from May 2007 to October 2009. Couples were
eligible to enroll in the study if they reported $3 sex acts in the
previous 3 months, planned to stay in Nairobi in their current
relationship for at least 2 years, and if one member of the couple
was HIV-1-infected and the other HIV-1 susceptible. Women who
were pregnant and participants using antiretroviral therapy at the
time of enrollment were excluded. At enrollment and at quarterly
follow-up visits, the HIV status of the uninfected partner was
determined using the DetermineH HIV–1/2 Rapid Test (Abbott
Laboratories, Abbott City, IL, USA) or Bioline Recombigen HIV
Test (Standard Diagnostics, Suwon City, Korea), with confirma-
tion by the VironostikaH HIV Uni-form II Ag/Ab ELISA kit
(bioMérieux Inc., Durham, NC, USA). In the HIV-1-infected
partner, CD4+ T-cell counts were taken at enrollment and every
six months using a FACSCaliber flow cytometer (BD Biosciences,
Franklin Lakes, NJ, USA).
At enrollment, clinical staff administered a questionnaire to
obtain information on sociodemographic characteristics, sexual
history and behavior, history of Pap screening, and medical
history. Questionnaires were presented in English or Kiswahili,
depending on participant preference, and were administered
individually to ensure confidentiality. A medical examination was
also conducted during biannual study visits, which included
collection of a cervical Pap smear. All participants with abnormal
cervical cytology were followed up with a repeat Pap test or
colposcopy and biopsy as recommended.
Assessment of Women’s Knowledge and Beliefs
Regarding Cervical Cancer
At the final study visit, up to two years after study enrollment,
clinical staff administered an extended questionnaire to obtain
additional information on male circumcision, pregnancy history,
domestic violence, ARV medication history, and cervical cancer
and screening. Relevant questions fell into three categories to
assess women’s: 1) knowledge of HPV and the causes and
prevention of cervical cancer, 2) attitudes towards Pap smear
screening after having had biannual screening in the study, and 3)
attitudes towards routine Pap smear screening, self-sampling and
HPV vaccination. Specifically, participants were asked if they had
ever heard of HPV and if they knew the cause of cervical cancer or
how to prevent it. Participants gave detailed histories of Pap smear
screening prior to the study or the reasons why they had never had
any screening, and were also asked about future intentions for Pap
smear screening. Women rated their level of pain during study-
conducted Pap smears, beliefs of cultural acceptability, and
feelings of necessity of Pap smear screening. Finally, women were
asked if they would feel comfortable collecting their own vaginal
samples at home and if they would consider HPV vaccination if it
were offered at no or low cost. No intervention or education on
cervical cancer and screening was provided during the study unless
medically indicated, and all responses were based on women’s
one-time self-report.
Written informed consent was obtained from all participants.
The study was conducted according to procedures approved by
the University of Washington Institutional Review Board and the
Kenyatta National Hospital Ethics and Research Committee.
Statistical Analysis
A descriptive summary of knowledge and acceptability overall
and stratified by HIV-status is presented. The numbers and
percentages of each response are presented. Measures of Pap
smear acceptability, necessity and pain-level are based on a scale
of 0 to 100 and women’s responses are summarized by the mean,
median and interquartile range. Exact logistic regression was used
to calculate unadjusted odds ratios and 95% confidence intervals
to describe the associations between baseline socioeconomic
indicators and medical and sexual history and: 1) having ever
had a Pap smear prior to study enrollment, 2) having ever heard of
human papillomavirus, 3) knowing that Pap smear screening is
conducted to prevent invasive cervical cancer, and 4) feeling that
Pap smears are completely acceptable (rating of 100) versus less
than completely acceptable. All analyses were conducted using
SAS version 9.2 (SAS, Cary, NC, USA).
Results
Study Population
We interviewed 409 women from HIV-1-discordant couples,
268 (65%) of whom were HIV-positive at baseline with a median
CD4+ T-cell count of 463 (interquartile range [IQR] 311–681;
Table 1). The median age in the study population was 29 years
(IQR 25–34), and the majority of women (97%) were married and
had completed at least primary education (8 years). HIV-negative
and positive participants were very similar, although HIV-negative
women were slightly more likely to be married (99% vs. 95%),
earn an income (35% vs. 28%), have never smoked (94% vs. 92%),
be on hormonal contraceptive (24% vs.16%) and have fewer
lifetime sexual partners (median 2 vs. 3) compared to HIV-positive
women.
Pap Smears, Self-Sampling, and HPV Vaccination
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Knowledge and Beliefs Regarding Cervical Cancer
We assessed knowledge of cervical cancer, HPV, and screening
among both HIV-negative and HIV-positive women (Table 2).
HIV-positive women tended to be more aware that ‘‘HPV, a virus,
or a sexually transmitted infection’’ causes cervical cancer
compared to HIV-negative women (24% vs. 18%). While a
substantial number of women did not know the cause of cervical
cancer (78%), most women (69%) knew that Pap smears are used
to test for cervical cancer. However, 82% of women did not know
that Pap smear screening is an important part of preventing, not
just detecting, cervical cancer. Nearly a quarter of women cited
condom use and 13% reported being faithful to their partners as
ways in which cervical cancer can be prevented. Only 18% of
women had ever heard of HPV, and of these, 64% knew that HPV
is transmitted through sexual intercourse and 35% did not know
any mode of HPV transmission.
Very few women (19% HIV-negative and 11% HIV-positive)
reported having had a Pap smear prior to the study. Of those who
reported having a Pap smear prior to enrollment in the study, most
had been done as part of routine care (42%) or as part of a prior
research study (19%) and the remaining were conducted for
unknown reasons (23%). Those who had never had a Pap smear
reported that they did not get screened because they did not know
what a Pap smear was or why they needed one (77%). After having
at least two Pap smears as part of the study protocol, nearly all
women (93%) said that they would seek out Pap screening in the
future, with the hospital being the most commonly cited place at
which they can be screened. Three-quarters of women said they
would be willing to pay up to 400 Kenyan shillings for a Pap smear
(approximately 5 US dollars).
When asked about methods of screening and prevention,
including self-sampling for HPV testing and HPV vaccination, the
majority of the women (82%) reported that they would be
comfortable using an at-home cervico-vaginal self-sampling
device. In fact, 84% of all women said they would prefer this
method over having a sample collected in a clinic. Despite their
willingness to consider self-sampling, the majority of women (91%)
had concerns regarding self-sampling, with the ability to properly
collect the sample being the most commonly cited concern (67%).
HIV-negative women were slightly more likely to report no
concerns (16%) as compared to HIV-positive women (5%). Nearly
all HIV-negative (94%) and HIV-positive women (94%) said they
would get a vaccine to prevent cervical cancer if offered to them in
the future at no or low cost.
When asked about the level of acceptability, pain, and necessity
that they felt towards Pap smear screening, nearly all women
(95%) gave Pap smears the highest possible rating for necessity
(Figure 1). About half of women (47%) gave Pap smears the
highest possible rating for acceptability (100 on a scale from 0 to
100; median = 80 (IQR 10–100)), while 21% felt they were
completely unacceptable. When the women, who had undergone
biannual screening as part of the study, were asked to rate the level
of pain associated with Pap smears, 73% of the women reported
the lowest level of pain (0 on a scale from 0 to 100; n = 300) and
only 3% (n = 12) gave a rating of $50.
Correlates of Pap Smear, Knowledge and Acceptability
Women age 30 years and older (odds ratio [OR]: 3.6, 95%
confidence interval [CI]: 1.9, 7.2), with at least a secondary
education (OR = 2.0, 95% CI: 1.1, 3.7), who had ever heard of
HPV (OR = 2.2, 95% CI: 1.1, 4.2) or knew that Pap smears were
used to prevent invasive cervical cancer (OR = 1.7, 95% CI: 0.8,
3.5) were more likely to have ever had a Pap smear prior to
enrolling in the study (Table 3). Women who were HIV-
Table 1. Baseline characteristics of 409 HIV-negative and HIV-positive adult women.
HIV-negative (N = 141) HIV-positive (N = 268) All women (N = 409)
n (%) or median (IQR)
Age 29 (26–35) 28 (24–34) 29 (25–34)
Married 139 (99%) 256 (96%) 395 (97%)
Years of education 8 (7–12) 8 (7–12) 8 (7–12)
Earn monthly income 49 (35%) 76 (28%) 125 (31%)
History of smoking1
Never 133 (94%) 246 (92%) 379 (93%)
Current 1 (1%) 4 (2%) 5 (1%)
Past 7 (5%) 18 (7%) 25 (6%)
Number of live births 2 (1–4) 2 (1–3) 2 (1–3)
Abnormal Pap smear 26 (19%) 62 (25%) 88 (23%)
Current hormonal contraception use2 33 (24%) 44 (16%) 77 (19%)
Age at sexual debut 18 (16–20) 18 (16–19) 18 (16–19)
Lifetime number of sex partners 2 (2–3) 3 (2–4) 3 (2–4)
Condom use at last sex 111 (95%) 227 (94%) 338 (94%)
CD4 T-cell count3 – 463 (311–681) –
1History of smoking: $1 cig/day for $6 consecutive months.
2Hormonal contraception includes injection, oral and implant-based contraceptive.
3Evaluated among HIV-1 infected female participants (n = 268).
Missing data: Abnormal Pap smear at baseline (n = 25); Hormonal contraception (n = 1); Median age at sexual debut (n = 1); Lifetime number of partners (n = 1); Condom
use at last sex (n = 51); CD4 T cell (n = 17).
Abbreviations: HIV (human immunodeficiency virus); N (number); IQR (interquartile range); CD4 T-cell (T helper cells with cluster of differentiation 4 receptor).
doi:10.1371/journal.pone.0040766.t001
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Table 2. HPV, Pap, and screening knowledge and acceptability by HIV infection status among adult women1.
HIV-negative (n = 141) HIV-positive (n = 268) All women (n = 409)
N (%) N (%) N (%)
Reasons why Pap smear screening is conducted
To test for STIs 24 (17%) 36 (13%) 60 (15%)
To test for cervical cancer 100 (71%) 184 (69%) 284 (69%)
To test for other cancers 0 (0%) 6 (2%) 6 (1%)
To determine pregnancy 0 (0%) 0 (0%) 0 (0%)
Don’t know 23 (16%) 52 (19%) 76 (19%)
Causes of cervical cancer
Smoking 1 (1%) 3 (1%) 4 (1%)
Poor sanitation/hygiene 0 (0%) 5 (2%) 5 (1%)
Multiple sex partners 18 (13%) 31 (12%) 49 (12%)
Pregnancy-related 1 (1%) 2 (1%) 3 (1%)
An STI/virus/HPV 26 (18%) 63 (24%) 89 (22%)
Exposure to pollution 8 (6%) 6 (2%) 14 (3%)
Family planning methods 0 (0%) 7 (3%) 7 (2%)
HIV/immunosuppression 0 (0%) 3 (1%) 3 (1%)
Other4 17 (12%) 11 (4%) 28 (7%)
Don’t know 72 (51%) 141 (53%) 213 (52%)
Ways in which cervical cancer can be prevented
Use condoms 28 (20%) 59 (22%) 87 (21%)
Be faithful to your partner 19 (13%) 34 (13%) 53 (13%)
Have Pap smear screening 28 (20%) 46 (17%) 74 (18%)
Proper hygiene and washing 5 (4%) 15 (6%) 20 (5%)
Get a vaccine 7 (5%) 9 (3%) 16 (4%)
Can’t prevent 2 (1%) 3 (1%) 5 (1%)
Other5 6 (4%) 15 (6%) 21 (5%)
Not known 50 (35%) 104 (39%) 154 (38%)
Ever heard of HPV 28 (20%) 47 (18%) 75 (18%)
If yes, ways in which HPV is transmitted2
Sexual intercourse 18 (64%) 30 (64%) 48 (64%)
Touching infected person 1 (4%) 0 (0%) 1 (1%)
Coughing 0 (0%) 0 (0%) 0 (0%)
Contaminated food 0 (0%) 0 (0%) 0 (0%)
Not Known 9 (32%) 17 (36%) 26 (35%)
Ever Pap smear prior to study enrollment 27 (19%) 30 (11%) 57 (14%)
If yes, where2
Emergency room 1 (4%) 0 (0%) 1 (2%)
Private doctor 3 (11%) 1 (3%) 4 (7%)
Prenatal care 1 (4%) 1 (3%) 2 (4%)
Family planning clinic 5 (19%) 3 (10%) 8 (14%)
Hospital 12 (44%) 12 (40%) 24 (42%)
Research study 2 (7%) 11 (37%) 13 (23%)
Screening campaign/program 3 (11%) 0 (0%) 3 (5%)
If yes, why2
Routine care 13 (48%) 11 (37%) 24 (42%)
Bleeding 2 (7%) 1 (3%) 3 (5%)
Abdominal pain 2 (7%) 1 (3%) 3 (5%)
Research study 2 (7%) 9 (30%) 11 (19%)
Other/unknown 7 (26%) 6 (20%) 13 (23%)
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seropositive (OR = 0.5, 95% CI: 0.3, 1.0) or used a condom the
last time they had sex prior to baseline (OR = 0.2, 95%CI: 0.1,
0.6) were less likely to have a history of Pap smear screening.
Education, knowledge of HPV, HIV-status and condom use
remained significantly associated with ever having a previous Pap
smear after adjusting for age.
Women with at least a secondary education compared to less
than a secondary education (OR = 3.2, 95%CI: 1.8, 5.8), those
who had ever had a Pap smear prior to enrollment in the study
compared to never previously screened (OR = 2.2, 95%CI: 1.1,
4.2), and those who knew compared with those who did not know
that Pap smears were conducted to as part of preventing cervical
cancer (OR = 2.4, 95%CI: 1.3, 4.4) were more likely to have heard
of HPV. Similarly, women with at least a secondary education
compared to less than a secondary education (OR = 2.2, 95%CI:
1.3, 3.9) and those who had ever versus never heard of HPV
(OR = 2.4, 95%CI: 1.3, 4.4) were more likely to know that Pap
smears can identify cervical abnormalities before cancer develops
Table 2. Cont.
HIV-negative (n = 141) HIV-positive (n = 268) All women (n = 409)
N (%) N (%) N (%)
If no, why3
Didn’t know what they were/why needed 86 (75%) 186 (78%) 272 (77%)
Heard they were uncomfortable 1 (1%) 1 (0%) 2 (1%)
Couldn’t afford 2 (2%) 4 (2%) 6 (2%)
Didn’t know where to get 3 (3%) 10 (4%) 13 (4%)
Other/unknown 10 (9%) 15 (6%) 25 (7%)
Seek Pap screening in future 133 (94%) 247 (92%) 380 (93%)
If yes, where do you believe you can obtain a Pap smear2
Hospital 114 (86%) 211 (85%) 325 (86%)
Prenatal care 3 (2%) 0 (0%) 3 (1%)
VCT 1 (1%) 2 (1%) 3 (1%)
Family planning clinic 6 (5%) 18 (7%) 24 (6%)
Emergency room 0 (0%) 0 (0%) 0 (0%)
Private doctor 4 (3%) 4 (2%) 8 (2%)
Other 7 (5%) 21 (9%) 28 (7%)
If yes, how much would you be willing to pay for a Pap smear2
0 Ksh 7 (5%) 14 (6%) 21 (6%)
1 to 400 Ksh 100 (75%) 180 (73%) 280 (74%)
401–999 Ksh 15 (11%) 33 (13%) 48 (13%)
1000+ Ksh 9 (7%) 17 (7%) 26 (7%)
Prefer at-home self-sampling to assess cancer risk5 122 (87%) 221 (82%) 343 (84%)
Comfortable using a self-sampling device5 121 (86%) 216 (81%) 337 (82%)
Potential concerns regarding self-sampling
Proper sample collection 84 (60%) 189 (71%) 273 (67%)
Pain from inserting device 5 (4%) 14 (5%) 19 (5%)
Stretch the vaginal canal 3 (2%) 0 (0%) 3 (1%)
Unable to insert the device into the vagina 6 (4%) 18 (7%) 24 (6%)
Interpreting results 4 (3%) 20 (7%) 24 (6%)
Other7 20 (14%) 41 (15%) 61 (15%)
No concerns 23 (16%) 14 (5%) 37 (9%)
Ever get a vaccine to prevent cervical cancer if no or low cost 132 (94%) 253 (94%) 385 (94%)
1Responses for multiple option questions are not mutually exclusive so the total percentage may sum to $100%.
2Denominator includes only the women who responded ‘yes’ to the above question.
3Denominator includes only the women who responded ‘no’ to the above question.
4Other includes condom use, douching, birth at older ages, stress, taking antiretroviral treatment.
5Other includes avoid douching, avoid sexually transmitted infections, avoid condom use.
6Explanation provided to participants: There is a new method that can be used to assess a women’s risk of cervical cancer without going to a medical clinic. It is a
vaginal self-sampling device that you would use in your own home. Would you prefer to take a vaginal sample yourself, using a cotton swab similar to a tampon, in the
privacy of your home in order to determine if you are at risk of cervical cancer? Would you feel comfortable inserting the swab into your vagina?
7Other includes: upset partner, beliefs against inserting objects into vagina, side effects from using device, frequency of testing, where to get treatment, device getting
stuck in vagina.
Abbreviations: N (number); % (percentage); HIV (human immunodeficiency virus); STI (sexually transmitted infection); HPV (human papillomavirus); IQR (interquartile
range); VCT (voluntary counseling and testing center); Ksh (Kenyan shilling).
doi:10.1371/journal.pone.0040766.t002
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in order to prevent the development of invasive cancer. A
woman’s history of Pap smear screening (OR = 1.9, 95%CI: 1.1,
3.6), knowledge of HPV (OR = 1.7, 95%CI: 1.0, 3.0) and
knowledge that Pap smears are a tool to prevent invasive cervical
cancer (OR = 1.8, 95%CI: 1.1, 3.2) were associated with giving
routine Pap smear screening the highest possible rating for
acceptability. Although education was associated with a history of
Pap smear screening, knowledge of HPV and knowledge that Pap
smears are used in the prevention of cervical cancer, education
was not associated with acceptability of Pap smears (OR = 1.0,
95% CI: 0.7, 1.5).
Discussion
The majority of women knew that Pap smears are used to detect
cervical cancer (69%), but very few knew that routine Pap
screening is the main way to prevent cervical cancer (18%). Most
women did not know the cause of cervical cancer (78%) and only
18% had ever heard of HPV. However, it was reassuring to find
that most women held positive attitudes towards future Pap smear
screening, self-sampling, and HPV vaccination. Our findings
highlight the need to educate and reinforce to women that routine
Pap smear screening is a key part of preventing invasive cervical
cancer so that the fear of being diagnosed with cancer is not a
barrier to screening.
Despite the fact that knowledge of HPV was very low in our
cohort, almost all women reported that they would be willing to be
vaccinated against HPV if the vaccine was available at no or low
cost. This finding is similar to other studies [28,29], including one
from Kenya which found that 95% of women would likely vaccinate
their daughters to prevent cervical cancer [9]. However, this
previous comprehensive vaccine assessment study found that only
31% of those women still said they would vaccinate their daughter if
it took three injections and 75% of women said they would only pay
100 Kenyan shillings (approximately 1.25 United States Dollars
[USD]) out of pocket to vaccinate their daughter. Current
generation prophylactic HPV vaccines cost approximately
375 USD in developed countries and require three injections over
a 6 month period. However, the GAVI Alliance now includes the
HPV vaccine on its list of childhood vaccines available for funding
in resource-limited countries. Also, studies are currently underway
to assess the efficacy of a shortened 1 or 2 dose vaccine
administration schedule.
Consistent with previous studies that document low uptake of
Pap smear screening in sub-Saharan Africa, previous Pap smear
screening was low in our cohort, with most women (86%)
reporting never having had a Pap smear prior to joining the study
[30,31]. It was interesting to find that even though HIV-positive
women are generally more likely to be in contact with the
healthcare system, and despite the recognized link between HIV
and cervical precancer [32,33] and the recommendation for
women to have biannual screening during the first year after HIV
diagnosis, HIV-positive women were less likely to have had a
previous Pap smear compared to HIV-negative women. This
highlights the importance of integrating cervical cancer screening
and management with routine HIV care and treatment programs,
as suggested by the 2011 national guidelines for antiretroviral
therapy in Kenya [34].
Without an intervention or educational campaign, it is likely
that the strongest predictor of future screening is having been
screened in the past. Identifying the characteristics of women who
have and have not had previous screening can help to target
screening and outreach efforts. In this cohort, women with less
education, who were HIV-positive, or didn’t have knowledge of
HPV or Pap smears, were less likely to have had previous Pap
smear screening. Given the cross-sectional study design, it is
unclear whether women learned of HPV during Pap smear
screening or whether they learned about HPV from other sources
and thus sought out cervical cancer screening. However, in a
setting such as Nairobi, where Pap smear screening is available,
although access and campaigns are limited, and where HPV
testing is now being advertised, it is likely that women who had
previous Pap smears for a research study, routine care or
diagnostic purposes learned of HPV during or in response to
Figure 1. Women’s response regarding their feelings of Pap smear acceptability, feelings of necessity, and how painful they found
Pap smears to be over two years of biannual screening. The open star symbol represents mean level of response; the closed circle represents
median level of response; the thick gray line represents the interquartile range of responses.
doi:10.1371/journal.pone.0040766.g001
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N (%) OR (95% CI)
Knowledge of








N (%) OR (95% CI)
Age
,30 years 16 (7%) 1 (ref) 39 (18%) 1 (ref) 39 (18%) 1 (ref) 103 (46%) 1 (ref)
$30 years 41 (22%) 3.6 (1.9, 7.2) 36 (20%) 1.1 (0.7, 1.9) 35 (20%) 1.1 (0.6, 1.9) 90 (48%) 1.1 (0.7, 1.6)
Married
No 0 (0%) 1 (ref) 4 (29%) 1 (ref) 3 (21%) 1 (ref) 6 (43%) 1 (ref)
Yes 57 (15%) 3.3 (0.5, IN) 71 (18%) 0.6 (0.2, 2.5) 71 (18%) 0.8 (0.2, 4.6) 187 (47%) 1.2 (0.4, 4.3)
Education
Primary or below (#8) 23 (10%) 1 (ref) 24 (11%) 1 (ref) 29 (13%) 1 (ref) 107 (47%) 1 (ref)
Secondary or above (.8) 34 (19%) 2.0 (1.1, 3.7) 51 (28%) 3.2 (1.8, 5.8) 45 (25%) 2.2 (1.3, 3.9) 86 (47%) 1.0 (0.7, 1.5)
Employed/earning income
No 39 (14%) 1 (ref) 50 (18%) 1 (ref) 48 (17%) 1 (ref) 139 (49%) 1 (ref)
Yes 18 (15%) 1.1 (0.5, 2.0) 25 (20%) 1.2 (0.6, 2.0) 26 (21%) 1.3 (0.7, 2.2) 54 (43%) 0.8 (0.5, 1.2)
History of smoking5
Never 55 (15%) 1 (ref) 69 (18%) 1 (ref) 69 (18%) 1 (ref) 185 (49%) 1 (ref)
Ever 2 (7%) 0.5 (0.1, 1.9) 6 (21%) 1.2 (0.4, 3.1) 5 (17%) 0.9 (0.3, 2.5) 8 (27%) 0.4 (0.1, 0.9)
Number of live births
0 to 1 10 (9%) 1 (ref) 28 (25%) 1 (ref) 29 (26%) 1 (ref) 51 (45%) 1 (ref)
2 to 3 29 (15%) 1.8 (0.8, 4.2) 33 (17%) 0.6 (0.3, 1.1) 33 (17%) 0.6 (0.3, 1.1) 95 (48%) 1.1 (0.7, 1.9)
4+ 18 (18%) 2.3 (0.9, 5.8) 14 (15%) 0.5 (0.2, 1.1) 12 (12%) 0.4 (0.2, 0.9) 47 (47%) 1.1 (0.6, 1.9)
Hormonal contraception6
No 47 (14%) 1 (ref) 58 (18%) 1 (ref) 60 (18%) 1 (ref) 159 (48%) 1 (ref)
Yes 10 (13%) 0.9 (0.4, 1.9) 17 (22%) 1.3 (0.7, 2.5) 14 (18%) 1.0 (0.5, 1.9) 34 (44%) 0.9 (0.5, 1.5)
Age at sexual debut
,18 years 21 (11%) 1 (ref) 30 (18%) 1 (ref) 24 (12%) 1 (ref) 97 (50%) 1 (ref)
$18 years 36 (17%) 1.6 (0.9, 3.1) 45 (21%) 1.4 (0.8, 2.5) 50 (23%) 2.1 (1.2, 3.7) 96 (44%) 0.8 (0.5, 1.2)
Lifetime number of sex partners
,4 31 (12%) 1 (ref) 50 (19%) 1 (ref) 50 (19%) 1 (ref) 122 (46%) 1 (ref)
$4 26 (18%) 1.7 (0.9, 3.0) 25 (17%) 0.9 (0.5, 1.5) 24 (17%) 0.8 (0.5, 1.5) 71 (49%) 1.1 (0.7, 1.7)
Condom use at last sex
No 8 (40%) 1 (ref) 1 (5%) 1 (ref) 7 (35%) 1 (ref) 12 (60%) 1 (ref)
Yes 41 (12%) 0.2 (0.1, 0.6) 65 (20%) 4.6 (0.7, 194.4) 62 (18%) 0.4 (0.2, 1.3) 157 (46%) 0.6 (0.2, 1.6)
HIV-status
Seronegative 27 (19%) 1 (ref) 28 (20%) 1 (ref) 28 (20%) 1 (ref) 67 (48%) 1 (ref)
Seropositive 30 (11%) 0.5 (0.3, 1.0) 47 (18%) 0.8 (0.5, 1.5) 46 (17%) 0.8 (0.5, 1.5) 126 (47%) 1.0 (0.6, 1.5)
Abnormal cytology at baseline
No 43 (15%) 1 (ref) 52 (18%) 1 (ref) 57 (19%) 1 (ref) 133 (45%) 1 (ref)
Yes 10 (11%) 0.8 (0.3, 1.6) 18 (21%) 1.2 (0.6, 2.2) 14 (16%) 0.8 (0.4, 1.5) 47 (53%) 1.4 (0.8, 2.3)
Ever previous Pap
No – – 58 (17%) 1 (ref) 59 (17%) 1 (ref) 156 (45%) 1 (ref)
Yes – – 17 (30%) 2.2 (1.1, 4.2) 15 (26%) 1.7 (0.8, 3.5) 35 (61%) 1.9 (1.1, 3.6)
Knowledge of HPV
No 39 (12%) 1 (ref) – – 51 (16%) 1 (ref) 147 (45%) 1 (ref)
Yes 17 (23%) 2.2 (1.1, 4.2) – – 23 (31%) 2.4 (1.3, 4.4) 44 (59%) 1.7 (1.0, 3.0)
Knowledge of Pap to prevent ICC
No 42 (13%) 1 (ref) 52 (16%) 1 (ref) – – 149 (44%) 1 (ref)
Yes 15 (20%) 1.7 (0.8, 3.5) 23 (31%) 2.4 (1.3, 4.4) – – 44 (59%) 1.8 (1.1, 3.2)
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screening. In addition, these findings are consistent with a previous
study of cervical cancer patients and non-patients in Nairobi,
which found a lower level of education and lack of knowledge of
cervical cancer to be associated with a decreased likelihood of
having had previous pap screening [9]. Previous studies have also
shown that knowledge of cervical cancer and Pap smears can
influence the uptake of cervical cancer screening services [35,36].
In our study, women who had heard of HPV and knew that Pap
smears are used to prevent invasive cervical cancer were far more
likely to find Pap screening 100% acceptable and necessary as
compared to women without knowledge of HPV and the role of
Pap smears in cervical cancer prevention.
Women’s knowledge and attitudes were self-reported when they
exited the study so there was no follow-up to confirm their feelings
or intentions. Pap smear screening conducted during the study
may have influenced women’s perception towards Pap smear
acceptability, as compared to women who have never been
screened. However, after having at least one Pap smear during the
study, women reported little physical discomfort associated with
Pap smear screening and most responded positively toward future
use of a self-sampling device and HPV vaccination. All women in
our cohort were in stable, HIV-discordant partnerships and so
their responses may not be generalizable to other HIV-negative
and HIV-positive women in the general population. However, this
is a very relevant population of women since they are of screening
age, HIV-positive or at risk for HIV, and many are mothers with
daughters potentially eligible for HPV prophylactic vaccination.
Furthermore, very little data exist on women’s knowledge and
attitudes towards cervical cancer and prevention, especially from
East Africa where the incidence and mortality rate of cervical
cancer are one of the highest worldwide [1]. Our ability to
examine within one population attitudes towards both traditional
screening methods, such as Pap smears, and towards new
alternative methods, such as the use of self-sampling and HPV
vaccination, does differentiate this study from previous surveys by
providing new data on acceptability and correlates of several
modalities of cervical cancer prevention. These data are an
important first step to developing and successfully implementing
effective and acceptable screening programs. Community-based
assessment of knowledge and acceptability, including women who
have never had Pap smear screening and women who have used
self-sampling devices, is an important next step to obtain
information that reflects the diversity of the target population.
Despite low levels of knowledge of HPV and that the fact that
Pap smears are a tool to prevent, not just detect, cervical cancer,
women reported a high-level of acceptability for cervical cancer
prevention measures, including Pap screening, HPV vaccination,
and self-sampling. Our findings highlight the need for education
regarding the cause and prevention of cervical cancer. Currently
over 100 sites in Kenya offer regular screening, however,
awareness is low and cervical cancer screening coverage for all
women age 18–69 years is only 3.2% [5]. Therefore, start-up of a
successful screening program requires bringing the resources into
the community but also mobilizing the unscreened population to
participate in the program. Data from this study can help inform
educational and outreach programs to target high-risk women,
with the goal of eliminating cervical cancer worldwide through the
use of various screening and prevention tools.
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